Document is current
Any future updates will be listed below
-
Authors
Thomas, Anish https://orcid.org/0000-0003-3293-3115
Takahashi, Nobuyuki https://orcid.org/0000-0002-8592-6528
Oplustil O’Connor, Lenka https://orcid.org/0000-0001-7580-1572
Redon, Christophe E.
Mohindroo, Chirayu https://orcid.org/0000-0002-5825-3356
Sciuto, Linda
Pongor, Lorinc
Schmidt, Keith T.
Steinberg, Seth M.
Aladjem, Mirit I. https://orcid.org/0000-0002-1875-3110
Figg, William Douglas https://orcid.org/0000-0003-2428-5613
O’Connor, Mark J. https://orcid.org/0000-0003-1823-625X
Pommier, Yves
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (ZIA BC 011793)
- License Information
-
More Information
Article History
Received: 12 March 2025
Accepted: 12 September 2025
First Online: 27 October 2025
Competing interests
: The Authors declare the following competing interests: A.T. received grants to the NCI from EMD Serono Research and Development, AstraZeneca, Gilead Sciences, and ProLynx during the conduct of the study. L.O.O. and M.J.O. are full-time employees and shareholders at AstraZeneca. C.E.R. is a named inventor on a patent related to methods and kits (enzyme-linked immunosorbent assay) for measuring and quantifying DNA double-strand breaks using γH2AX and H2AX; however, this technique was not used in the present study. N.T., C.M., L.S., L.P., K.T.S., S.M.S., M.I.A., W.D.F. and Y.P. declare no competing interests.
